第10章 腰痛市場

第11章 疼痛治療藥的研究開發趨勢

第12章 疼痛治療藥市場上未滿足需求

目前止痛藥的需求高漲中的臨床性效果

目前疼痛治療藥的安全性不穩定

類鴉片物質的濫用

忽視某種程度的疼痛患者人口

投藥療法的改善

便利性高的給藥途徑

動物疼痛模式的有效性

疼痛評估模式的可靠性

第13章 對疼痛治療藥開發平台的關注

第14章 疼痛治療藥市場分析

第15章 企業概要

第16章 參考文獻

圖表清單

目錄

Pain continues to represent major clinical, social and economic challenges. Globally, 1.5 billion people suffer from moderate to severe chronic pain. Pain is the leading cause of disability in the US, affecting 116 million adults, more than heart disease, cancer and diabetes combined. The US annual cost of chronic pain ranges from a colossal $560 to $635 billion.

Despite two decades of intensive R&D effort, commercialization of new products has been limited. Current analgesics only provide modest pain relief, frequently carry black box safety warnings and are susceptible to abuse. Indeed, in the US, opioid abuse is described as a deadly epidemic.

An assessment of the financial pain market with forecasts to 2020 for over 70 leading branded analgesic products and key pipeline candidates

Report highlights:

The pain therapeutics market is crowded and heavily genericized. In 2015, the leading branded pain therapeutics market is worth $11.3 billion, down 13.5% from 2014 total revenues of $13.1 billion.

Opioids form the backbone of pain management. This trend is set to continue over the coming years thanks to their continued superior analgesic activity. Physicians should become increasingly more confident in prescribing opioids due the arrival of abuse-deterrent formulations. By 2020, the leading branded opioids will generate over $6.6 billion in worldwide revenues.

Pain R&D is challenging, expensive and reliant on subjective outcome measures. Therefore, industry must revise their R&D strategies to gain success in this market. The FDA's 2014 Draft Guidance for Industry Analgesic Indications: Developing Drug and Biological Products should provide some clarity for pain developers, as this was indeed the first guidance update in over 20 years.